FDA 483 - Nesher Pharmaceuticals (USA) LLC - May 31, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Nesher Pharmaceuticals (USA) LLC in Bridgeton, MO, revealed significant deficiencies across multiple areas of their drug manufacturing operations. The firm failed to adequately validate test methods, thoroughly investigate out-of-specification results and product complaints, and maintain proper controls over computer systems. These issues indicate a lack of adherence to cGMP regulations, posing potential risks to product quality and patient safety.
ID · 55cc577c-2caf-41a9-976a-6899e529683d